{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:10:35Z","timestamp":1759533035491,"version":"build-2065373602"},"reference-count":59,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission Horizon 2020","doi-asserted-by":"publisher","award":["643381","643558"],"award-info":[{"award-number":["643381","643558"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["CP13\/00174","PI16\/01511","PI17\/01511"],"award-info":[{"award-number":["CP13\/00174","PI16\/01511","PI17\/01511"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CIBERES","award":["CB06\/06\/0031"],"award-info":[{"award-number":["CB06\/06\/0031"]}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.arbres.2018.11.002","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T17:34:03Z","timestamp":1545845643000},"page":"373-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["How Far Are we Away From an Improved Vaccine For Tuberculosis? Current Efforts and Future Prospects"],"prefix":"10.1016","volume":"55","author":[{"given":"Cristina","family":"Vilaplana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere-Joan","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2017","series-title":"WHO Global tuberculosis report 2017 [Internet]","author":"WHO","key":"10.1016\/j.arbres.2018.11.002_bib0300"},{"key":"10.1016\/j.arbres.2018.11.002_bib0305","first-page":"238","article-title":"The global plan to stop TB, 2006\u20132015","volume":"10","author":"Raviglione","year":"2006","journal-title":"Int J Tuberculosis Lung Dis"},{"year":"2015","series-title":"WHO end TB strategy [Internet]","key":"10.1016\/j.arbres.2018.11.002_bib0310"},{"key":"10.1016\/j.arbres.2018.11.002_bib0315","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a017889","article-title":"Tuberculosis comorbidity with communicable and noncommunicable diseases","author":"Bates","year":"2015","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"10.1016\/j.arbres.2018.11.002_bib0320","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/ije\/22.6.1154","article-title":"Protective effect of bcg against tuberculous meningitis and miliary tuberculosis: a meta-analysis","volume":"22","author":"Rodrigues","year":"1993","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.arbres.2018.11.002_bib0325","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","article-title":"Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness","volume":"367","author":"Trunz","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2018.11.002_bib0330","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials","volume":"58","author":"Mangtani","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arbres.2018.11.002_bib0335","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1473-3099(15)00400-4","article-title":"Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study","volume":"16","author":"Nguipdop-Djomo","year":"2016","journal-title":"Lancet Infect Dis [Internet]"},{"key":"10.1016\/j.arbres.2018.11.002_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.g4643","article-title":"Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis","volume":"349","author":"Roy","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.arbres.2018.11.002_bib0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.01134","article-title":"What have we learnt about BCG vaccination in the last 20 years?","volume":"8","author":"Dockrell","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.arbres.2018.11.002_bib0350","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coi.2017.06.007","article-title":"BCG \u2014 old workhorse, new skills","volume":"47","author":"Gengenbacher","year":"2017","journal-title":"Curr Opin Immunol [Internet]"},{"key":"10.1016\/j.arbres.2018.11.002_bib0355","doi-asserted-by":"crossref","first-page":"e1001012","DOI":"10.1371\/journal.pmed.1001012","article-title":"The BCG world atlas: a database of global BCG vaccination policies and practices","volume":"8","author":"Zwerling","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.arbres.2018.11.002_bib0360","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1016\/j.vaccine.2011.05.023","article-title":"Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial","volume":"29","author":"Barreto","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.arbres.2018.11.002_bib0365","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2223\/JPED.1499","article-title":"BCG vaccine: efficacy and indications for vaccination and revaccination","volume":"82","author":"Barreto","year":"2006","journal-title":"J Pediatr (Rio J) [Internet]"},{"key":"10.1016\/j.arbres.2018.11.002_bib0370","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.arbres.2018.11.002_bib0375","doi-asserted-by":"crossref","first-page":"e106519","DOI":"10.1371\/journal.pone.0106519","article-title":"Revaccination of cattle with bacille Calmette-Gu\u00e9rin two years after first vaccination when immunity has waned, boosted protection against challenge with Mycobacterium bovis","volume":"9","author":"Parlane","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.arbres.2018.11.002_bib0380","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.vaccine.2006.07.020","article-title":"The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children","volume":"25","author":"Hesseling","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.arbres.2018.11.002_bib0385","first-page":"1","article-title":"BCG vaccination in HIV-infected children","volume":"2011","author":"Nuttall","year":"2011","journal-title":"Tuberc Res Treat [Internet]"},{"key":"10.1016\/j.arbres.2018.11.002_bib0390","first-page":"5035","volume":"33","author":"Moliva","year":"2016","journal-title":"Prospects in Mycobacterium bovis Bacille Calmette et Gu\u00e9rin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?"},{"key":"10.1016\/j.arbres.2018.11.002_bib0395","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/infdis\/jiv503","article-title":"Pulmonary but not subcutaneous delivery of BCG vaccine confers protection to tuberculosis-susceptible mice by an interleukin 17-dependent mechanism","volume":"213","author":"Aguilo","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.arbres.2018.11.002_bib0400","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tube.2016.09.004","article-title":"Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations","volume":"101","author":"Sharpe","year":"2016","journal-title":"Tuberculosis"},{"year":"2017","series-title":"TAG 2017 Pipeline Report. HIV, TB & HCV drugs, diagnostics, vaccines, preventive technologies, cure research, and immune-based and gene therapies in development. [Internet]","author":"Frick","key":"10.1016\/j.arbres.2018.11.002_bib0405"},{"key":"10.1016\/j.arbres.2018.11.002_bib0410","doi-asserted-by":"crossref","first-page":"e00439","DOI":"10.1128\/CVI.00439-16","article-title":"Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa","volume":"24","author":"Loxton","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.arbres.2018.11.002_bib0415","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3389\/fimmu.2017.01803","article-title":"MTBVAC: attenuating the human pathogen of tuberculosis (TB) toward a promising vaccine against the TB epidemic","volume":"8","author":"Gonzalo-Asensio","year":"2017","journal-title":"Front Immunol"},{"issue":"42.","key":"10.1016\/j.arbres.2018.11.002_bib0420","article-title":"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials","volume":"31","author":"Arbues","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.arbres.2018.11.002_bib0425","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1016\/j.vaccine.2014.03.047","article-title":"Therapeutic vaccines for tuberculosis \u2013 a systematic review","volume":"32","author":"Gr\u00f6schel","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.arbres.2018.11.002_bib0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2004.09.008","article-title":"Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis","volume":"23","author":"Cardona","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.arbres.2018.11.002_bib0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020404","article-title":"Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis","volume":"6","author":"Vilaplana","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.arbres.2018.11.002_bib0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089612","article-title":"Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection","volume":"9","author":"Nell","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.arbres.2018.11.002_bib0445","first-page":"1","article-title":"Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: a randomized, controlled trial of DAR-901","volume":"12","author":"Von Reyn","year":"2017","journal-title":"PLoS One [Internet]"},{"key":"10.1016\/j.arbres.2018.11.002_bib0450","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.4161\/hv.25280","article-title":"Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7)","volume":"9","author":"Efremenko","year":"2013","journal-title":"Vaccines [Internet]"},{"year":"2018","series-title":"TB prevention pipeline report 2018 [Internet]","author":"Treatment Action Group (TAG)","key":"10.1016\/j.arbres.2018.11.002_bib0455"},{"key":"10.1016\/j.arbres.2018.11.002_bib0460","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.1202870109","article-title":"Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes","volume":"109","author":"Kleinnijenhuis","year":"2012","journal-title":"Proc Natl Acad Sci [Internet]"},{"key":"10.1016\/j.arbres.2018.11.002_bib0465","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2018.11.002_bib0470","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.chom.2018.06.004","article-title":"Mechanisms of M. tuberculosis immune evasion as challenges to TB vaccine design","volume":"24","author":"Ernst","year":"2018","journal-title":"Cell Host Microbe [Internet]"},{"key":"10.1016\/j.arbres.2018.11.002_bib0475","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imr.12276","article-title":"B cells and antibodies in the defense against Mycobacterium tuberculosis infection","volume":"264","author":"Achkar","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.arbres.2018.11.002_bib0480","doi-asserted-by":"crossref","first-page":"11290","DOI":"10.1038\/ncomms11290","article-title":"T-cell activation is an immune correlate of risk in BCG vaccinated infants","volume":"7","author":"Fletcher","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.arbres.2018.11.002_bib0485","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01203","article-title":"TBVAC2020: advancing tuberculosis vaccines from discovery to clinical development","volume":"8","author":"Kaufmann","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.arbres.2018.11.002_bib0490","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.addr.2015.11.005","article-title":"Designing liposomal adjuvants for the next generation of vaccines","volume":"99","author":"Perrie","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.arbres.2018.11.002_bib0495","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93+GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"Penn-Nicholson","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2018.11.002_bib0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176784","article-title":"Multi-subunit BCG booster vaccine GamTBvac: assessment of immunogenicity and protective efficacy in murine and guinea pig TB models","volume":"12","author":"Tkachuk","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.arbres.2018.11.002_bib0505","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1473-3099(14)70886-2","article-title":"Changing route: aerosol vaccine against tuberculosis","volume":"14","author":"Rappuoli","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.arbres.2018.11.002_bib0510","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.vaccine.2016.01.062","article-title":"A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults","volume":"34","author":"Minhinnick","year":"2016","journal-title":"Vaccine [Internet]"},{"key":"10.1016\/j.arbres.2018.11.002_bib0515","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","article-title":"Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A","volume":"33","author":"Stylianou","year":"2015","journal-title":"Vaccine [Internet]"},{"key":"10.1016\/j.arbres.2018.11.002_bib0520","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tube.2016.07.005","article-title":"Safety and immunogenicity of the M72\/AS01Ecandidate tuberculosis vaccine in adults with tuberculosis: a phase II randomised study","volume":"100","author":"Gillard","year":"2016","journal-title":"Tuberculosis"},{"key":"10.1016\/j.arbres.2018.11.002_bib0525","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2018.11.002_bib0530","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.tube.2013.11.003","article-title":"A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data","author":"McShane","year":"2014","journal-title":"Tuberculosis"},{"key":"10.1016\/j.arbres.2018.11.002_bib0535","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijid.2017.01.030","article-title":"Experimental animal modelling for TB vaccine development","volume":"56","author":"Cardona","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"Mvi","key":"10.1016\/j.arbres.2018.11.002_bib0540","doi-asserted-by":"crossref","first-page":"199","DOI":"10.12688\/f1000research.13588.1","article-title":"Progress and challenges in TB vaccine development","volume":"7","author":"Voss","year":"2018","journal-title":"F1000Research [Internet]"},{"key":"10.1016\/j.arbres.2018.11.002_bib0545","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/cir951","article-title":"Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis","volume":"54","author":"Andrews","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arbres.2018.11.002_bib0550","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fimmu.2017.00556","article-title":"What we have learned and what we have missed in tuberculosis pathophysiology for a new vaccine design: searching for the \u201cpink swan\u201d","volume":"8","author":"Cardona","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.arbres.2018.11.002_bib0555","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1098\/rsif.2008.0184","article-title":"Tuberculosis reinfection rate as a proportion of total infection rate correlates with the logarithm of the incidence rate: a mathematical model","volume":"6","author":"Uys","year":"2009","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.arbres.2018.11.002_bib0560","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1080\/21645515.2016.1205769","article-title":"Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines","volume":"12","author":"Harris","year":"2016","journal-title":"Hum Vaccines Immunother [Internet]"},{"key":"10.1016\/j.arbres.2018.11.002_bib0565","first-page":"1536","article-title":"The progress of therapeutic vaccination with regard to tuberculosis","volume":"16","author":"Cardona","year":"2016","journal-title":"Front Microbiol"},{"year":"2013","series-title":"Definitions and reporting framework for tuberculosis \u2013 2013 revision [Internet]","author":"World Health Organization","key":"10.1016\/j.arbres.2018.11.002_bib0570"},{"key":"10.1016\/j.arbres.2018.11.002_bib0575","first-page":"e71116","article-title":"Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update","volume":"8","author":"Wallis","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.arbres.2018.11.002_bib0580","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S2213-2600(15)00036-3","article-title":"Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies","volume":"3","author":"Kurbatova","year":"2015","journal-title":"Lancet Respir [Internet]"},{"key":"10.1016\/j.arbres.2018.11.002_bib0585","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1038\/s41598-017-03514-1","article-title":"Efficacy and safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial","volume":"7","author":"Sharma","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.arbres.2018.11.002_bib0590","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/cid\/civ609","article-title":"Perspectives on advances in tuberculosis diagnostics, drugs, and vaccines","author":"Schito","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289618304460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289618304460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:37:31Z","timestamp":1759531051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289618304460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0300289618304460"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2018.11.002","relation":{},"ISSN":["0300-2896"],"issn-type":[{"type":"print","value":"0300-2896"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How Far Are we Away From an Improved Vaccine For Tuberculosis? Current Efforts and Future Prospects","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2018.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}